Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"Comment on FDA Approval Pathways.","authors":"Shaojun Zhu, Bella Whalen, Thomas A Hope","doi":"10.2967/jnumed.126.273516","DOIUrl":"https://doi.org/10.2967/jnumed.126.273516","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Suspected Tumor Recurrence with Epidermal Growth Factor Receptor-Targeted [⁸⁹Zr]Zr-Panitumumab PET/CT.","authors":"Joseph Hoang, Kyrionna Golliday, Ashtyn McAdoo, Adam Rosenberg, Kamal Jouad, Eben Rosenthal, Michael C Topf","doi":"10.2967/jnumed.125.271333","DOIUrl":"https://doi.org/10.2967/jnumed.125.271333","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing ¹⁷⁷Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses.","authors":"Kyle Flannery, Paul F Cavanaugh, Kevin Steele","doi":"10.2967/jnumed.126.272999","DOIUrl":"https://doi.org/10.2967/jnumed.126.272999","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Conversation Between Stefano Fanti and Johannes Czernin.","authors":"Stefano Fanti, Johannes Czernin","doi":"10.2967/jnumed.126.273735","DOIUrl":"https://doi.org/10.2967/jnumed.126.273735","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective, Single-Center, Single-Arm, Exploratory Study of ¹⁷⁷Lu-LNC1010 Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors.","authors":"Wei Guo, Chunlei Fan, Yuhang Chen, Shan Yu, Guanming Yue, Tianzhi Zhao, Dan Ruan, Weizhi Xu, Hao Fu, Bishan Su, Lingyu Yu, Liang Zhao, Jingxiong Huang, Hua Wu, Jingjing Zhang, Xin Zhao, Xiaoyuan Chen, Haojun Chen","doi":"10.2967/jnumed.126.272607","DOIUrl":"https://doi.org/10.2967/jnumed.126.272607","url":null,"abstract":"<p><p>Rapid radiopharmaceutical clearance limits the efficacy of peptide receptor radionuclide therapy (PRRT) for the treatment of advanced neuroendocrine tumors (NETs). In this prospective, single-center, single-arm, investigator-initiated trial, we evaluated the safety and efficacy of ¹⁷⁷Lu-LNC1010-an optimized, long-acting somatostatin analog-in patients with progressive metastatic NETs. <b>Methods:</b> Twenty-two patients with unresectable, metastatic NETs and disease progression despite treatment with somatostatin analogs or tyrosine kinase inhibitors were enrolled in the study. Participants received up to 4 cycles of PRRT with ¹⁷⁷Lu-LNC1010 (3.3 GBq/cycle) at 8-wk intervals. Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0. The treatment response was evaluated using RECIST 1.1. Kaplan-Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). <b>Results:</b> The patients (13 men, 9 women; median age, 50.5 y) received 69 PRRT cycles in total. Treatment-related grade 3 or 4 hematologic toxicities were observed in 6 patients (27%). No grade 3 or higher nephrotoxicity or hepatotoxicity was recorded. The median absorbed tumor dose was 2.12 (interquartile range: 1.68-2.96) Gy/GBq. Response after PRRT was assessed in 18 patients. A partial response was achieved in 8 patients (44.0%), stable disease in 9 (50.0%), and progressive disease in 1 (5.6%). The objective response rate was 44.4%, and the disease control rate was 94.4%. After a median follow-up of 21.0 mo, the median PFS was 15.0 mo, and the median OS was not reached. <b>Conclusion:</b> PRRT with 3.3 GBq/cycle of ¹⁷⁷Lu-LNC1010 was well-tolerated and exhibited an acceptable safety profile. The objective response rate and disease control rate were high and positively correlated with improved PFS and OS. Appropriate patient selection and earlier intervention may further optimize the therapeutic benefit.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.","authors":"Matteo Bauckneht, Liliana Belgioia, Domenico Albano, Luca Triggiani, Flavia Linguanti, Luca Urso, Rosario Mazzola, Alessio Rizzo, Elisa D'Angelo, Francesco Dondi, Eneida Mataj, Gloria Pedersoli, Elisabetta Maria Abenavoli, Luca Vaggelli, Beatrice Detti, Naima Ortolan, Antonio Malorgio, Alessia Guarneri, Federico Garrou, Jacopo Passoni, Matilde Fiorini, Serena Grimaldi, Pietro Ghedini, Giuseppe Carlo Iorio, Antonella Iudicello, Guido Rovera, Giuseppe Fornarini, Elisa Zanardi, Diego Bongiovanni, Michela Marcenaro, Alessandra Agosti, Giorgia Timon, Matteo Salgarello, Manuela Racca, Mirco Bartolomei, Stefano Panareo, Umberto Ricardi, Francesco Bertagna, Filippo Alongi, Salvina Barra, Silvia Morbelli, Francesco Lanfranchi, Gianmario Sambuceti","doi":"10.2967/jnumed.125.271680","DOIUrl":"10.2967/jnumed.125.271680","url":null,"abstract":"<p><p>It is unclear whether the imaging modality used to guide metastasis-directed therapy (MDT) influences outcomes in oligometastatic castration-resistant prostate cancer (omCRPC). <b>Methods:</b> We performed an updated analysis of the PRECISE-MDT cohort, adding 27 patients to the original cohort. MDT guided by prostate-specific membrane antigen (PSMA) PET/CT, choline PET/CT, and conventional imaging was compared in 102 patients with omCRPC. The primary outcomes were biochemical recurrence-free survival and overall survival after adjustment for inverse probability of treatment weighting. <b>Results:</b> MDT was guided by conventional imaging in 20 (19.6%) patients, choline PET/CT in 56 (54.9%) patients, and PSMA PET/CT in 26 (25.5%) patients. PSMA PET/CT guidance yielded longer biochemical recurrence-free survival than did choline PET/CT (median not reached [NR] vs. 11.7 mo, <i>P</i> = 0.031) and conventional imaging (NR vs. 7.1 mo, <i>P</i> = 0.002). Overall survival favored PSMA PET/CT versus conventional imaging (NR vs. 46.0 mo, <i>P</i> = 0.036). <b>Conclusion:</b> PSMA PET/CT guidance was associated with improved clinical outcome, supporting its therapeutic relevance for MDT planning in omCRPC.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1409-1412"},"PeriodicalIF":9.1,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148229759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sub-0.5-mm Resolution PET Versus Autoradiography: Comparison of mGluR1 Concentrations in Mouse Brain.","authors":"Han Gyu Kang, Hideaki Tashima, Hidekatsu Wakizaka, Takeharu Minamihisamatsu, Tomoteru Yamasaki, Masayuki Fujinaga, Ming-Rong Zhang, Makoto Higuchi, Taiga Yamaya","doi":"10.2967/jnumed.125.271600","DOIUrl":"10.2967/jnumed.125.271600","url":null,"abstract":"<p><p>For mouse brain PET imaging with high quantification accuracy, ultrahigh resolution is essential. Metabotropic glutamate receptors are important molecular targets, linked to various neurologic diseases. Here, we report the comparison of in vivo mouse brain images obtained with sub-0.5-mm resolution PET and those obtained with autoradiography using 4-¹⁸F-fluoro-<i>N</i>-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-<i>N</i>-methylbenzamide (¹⁸F-FITM) that binds to metabotropic glutamate receptor subtype 1. <b>Methods:</b> We recently developed a sub-0.5-mm resolution PET scanner having an axial coverage of 23.4 mm and an inner diameter of 48 mm. The PET scanner comprises 32 depth-of-interaction detectors, each of which has staggered 3-layer lutetium-yttrium-orthosilicate crystal arrays with a pitch of 0.8 mm. A resolution phantom was used to evaluate the imaging performance of the PET scanner. Dynamic PET imaging was performed to evaluate the concentration changes of ¹⁸F-FITM at various mouse brain regions. In vivo metabotropic glutamate receptor imaging of a mouse brain was performed using ¹⁸F-FITM and the PET scanner. Subsequently, autoradiography images of the same mouse brain were obtained using ¹⁸F-FITM. <b>Results:</b> The 0.45-mm rod structure was resolved with the PET scanner. Time-activity curves of various mouse brain regions were obtained. The sub-0.5-mm resolution PET visualized ¹⁸F-FITM uptake in the mouse brain with high correlation to the autoradiography images. <b>Conclusion:</b> The sub-0.5-mm resolution PET opens up new opportunities for translational neuroscience research using mice models.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1503-1509"},"PeriodicalIF":9.1,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148166333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional Renal Assessment via Dynamic LAFOV ¹⁸F-FDG PET/CT in a Patient with Recurrent Extranodal Marginal-Zone Lymphoma.","authors":"Jonathan Kuten, Bradley J Beattie, Stephanie Chahwan, Heiko Schöder","doi":"10.2967/jnumed.126.272086","DOIUrl":"10.2967/jnumed.126.272086","url":null,"abstract":"<p><p>We report the case of a 72-y-old man with recurrent extranodal marginal-zone B-cell lymphoma who underwent dynamic long-axial-field-of-view ¹⁸F-FDG PET/CT. In addition to detecting extensive recurrent disease, a review of a maximum-intensity-projection cine derived from the dynamic acquisition demonstrated delayed uptake and excretion from the left kidney, consistent with impaired function. This incidental functional renal assessment supplemented standard anatomic imaging and influenced treatment management. This case highlights the emerging capability of dynamic long-axial-field-of-view ¹⁸F-FDG PET/CT to provide renal functional information in oncologic imaging.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1481-1483"},"PeriodicalIF":9.1,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MIRD Pamphlet No. 34, Part 2: Benchmarking of MIRDct Software for CT Organ Dose Estimation.","authors":"Gunjan Kayal, Juan Camilo Ocampo Ramos, Laura E Dinwiddie, Jared M Baggett, Robert J Dawson, Harry Marquis, Stefan K Wehmeier, Oleksandra Ivashchenko, Lukas M Carter, Wesley E Bolch, Adam L Kesner","doi":"10.2967/jnumed.125.271501","DOIUrl":"10.2967/jnumed.125.271501","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Accurate estimation of organ and effective doses in CT imaging is essential for risk assessment, protocol optimization, and personalized care in diagnostic radiology and nuclear medicine. We systematically benchmarked MIRDct, a freely available mesh phantom-based CT dose calculation software, against established reference software (National Cancer Institute Dosimetry System for Computed Tomography [NCICT] and VirtualDose [Virtual Phantoms]) by evaluating agreement between organ-absorbed doses and effective doses across representative scanners, phantoms, and protocols. &lt;b&gt;Methods:&lt;/b&gt; Organ absorbed and effective doses were calculated for adult and pediatric phantoms for whole-body (WB) and regional (head, chest, abdomen-pelvis [AP]) CT examinations. MIRDct uses mesh-based International Commission on Radiologic Protection (ICRP) reference phantoms with anatomically realistic organ surfaces, whereas NCICT and VirtualDose use voxel-based ICRP 110 and hybrid Rensselaer Polytechnic Institute/University of Florida phantom models, respectively. For each software, volumetric CT dose index (CTDIvol) values were obtained from the software interface using matched acquisition parameters; in MIRDct, these values were derived from scanner console-reported outputs for the corresponding protocol settings. Organ absorbed doses, dose coefficients, and effective doses were computed across 44 matched scanner-phantom-protocol configurations. Inter-software differences were summarized using medians and interquartile ranges. For regional protocols, organ-absorbed doses were stratified by irradiation category (in-field, partial-in-field, out-of-field), to assess field-dependent variability. &lt;b&gt;Results:&lt;/b&gt; CTDIvol​ values reported by the 3 software tools showed close agreement across matched protocol configurations, with median inter-software differences not exceeding 7%. For in-field organs, dose coefficients from NCICT and VirtualDose generally agreed with MIRDct values within ±25% across adult and pediatric head, chest, AP, and WB protocols, indicating good agreement in the primary beam region. Larger relative deviations occurred for partial-in-field and out-of-field organs, where doses were scatter-dominated; however, absolute organ doses were less than 2 mGy, limiting clinical relevance. Effective dose estimates showed similar concordance: differences were below 25% for all VirtualDose comparisons except head scans and for WB protocols, whereas adult chest and AP protocols differed by up to 40% relative to NCICT. These differences were associated with variations in phantom anatomy and fixed, pre-tabulated CTDIvol reference values in NCICT and VirtualDose, compared with protocol-specific, console-reported CTDIvol inputs in MIRDct. &lt;b&gt;Conclusion:&lt;/b&gt; MIRDct provides organ- and effective-dose estimates that are broadly consistent with established CT dosimetry tools, with agreement typically within ±25% for in-field organs and within a few milligray for absolute ","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1491-1502"},"PeriodicalIF":9.1,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PCa Detection in PI-RADS 4 and 5 Lesions: Comparison of [⁶⁸Ga]Ga-PSMA-11 PET/CT-Guided Robot-Assisted Biopsy Versus mpMRI Cognitive-Fusion TRUS-Guided Prostate Biopsy.","authors":"Rajender Kumar, Aravindh Ram, Santosh Kumar, Harmandeep Singh, Nandita Kakkar, Ujjwal Gorsi, Anupam Lal, Bhagwant Rai Mittal, Shrawan Kumar Singh","doi":"10.2967/jnumed.126.272036","DOIUrl":"10.2967/jnumed.126.272036","url":null,"abstract":"<p><p>Lesions with a Prostate Imaging-Reporting and Data System (PI-RADS) score of 4 or greater on multiparametric MRI (mpMRI) indicate a high likelihood of prostate cancer (PCa), and guidelines recommend a targeted biopsy. We aimed to compare the diagnostic performance of robotic arm-assisted [⁶⁸Ga]Ga-PSMA-11 PET/CT-guided prostate biopsy (PGPB) with mpMRI-directed cognitive-fusion transrectal ultrasound-guided biopsy (MCFB) in biopsy-naïve men with clinical findings suggestive of PCa. <b>Methods:</b> This prospective, single-center, randomized clinical trial (NCT05137561) enrolled biopsy-naïve men age 50-90 y with elevated levels of prostate-specific antigen (≥4 ng/mL) and abnormal digital rectal examination findings. All participants underwent mpMRI, and those with a PI-RADS score of 4 or greater were randomized into 2 arms. In arm 1, participants underwent PGPB for a [⁶⁸Ga]Ga-PSMA-avid lesion, and participants in arm 2 underwent MCFB. Participants in arm 1 with PET-negative findings subsequently underwent MCFB, and participants with negative biopsy results underwent PET and PGPB. The primary outcome was the detection of PCa. Secondary outcomes included complication rates and participant-reported pain. <b>Result:</b> Of the 267 participants enrolled, 81.3% (217) had lesions with a PI-RADS score of 4 or greater and were randomized to either PGPB (<i>n</i> = 112) or MCFB (<i>n</i> = 105). PCa was detected in 97.1% of participants (101/104) in arm 1 and 81.0% (85/105) in arm 2 (<i>P</i> < 0.05). PGPB showed higher diagnostic accuracy for PI-RADS 5 lesions (100% vs. 95.1%, <i>P</i> = 0.09). Major complications were observed in arm 2 only (<i>n</i> = 5). Arm 1 had significantly fewer complications (10.8% vs. 51.4%, <i>P</i> < 0.01), a lower median visual analog scale score for pain (3 vs. 5), and shorter procedure times. The core positivity rate was higher in arm 1 (60% ± 20%), despite obtaining fewer cores. <b>Conclusion:</b> [⁶⁸Ga]Ga-PSMA-11 PGPB demonstrated higher diagnostic performance, fewer complications, and better tolerability compared with MCFB. This approach enables integrated diagnosis and staging, offering a promising alternative for efficient, safe, and accurate evaluation of prostate cancer.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1401-1408"},"PeriodicalIF":9.1,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}